Last updated: February 13, 2026
What Is the Market Status and Price Projection for NDC 00169-4060?
NDC 00169-4060 corresponds to Vemurafenib, marketed under the brand name Zelboraf, a targeted therapy for melanoma with BRAF V600E mutation. This analysis covers current market dynamics, competitive landscape, regulatory environment, and future price expectations.
What Is the Current Market Environment for Vemurafenib (NDC 00169-4060)?
Market Size and Revenue
-
The global melanoma treatment market generated approximately $2.5 billion in 2022, with targeted therapies like Vemurafenib accounting for around 60% of sales in this segment.[1]
-
Vemurafenib's annual sales revenue peaked at $1.2 billion in 2021, driven by its approval for metastatic melanoma with BRAF V600E mutation.[2]
Competitive Landscape
-
Major competitors include Dabrafenib (Tafinlar), combined with Trametinib (Mekinist), both targeting BRAF and MEK mutations.
-
Launch of combined BRAF and MEK inhibitor regimens has shifted market share, with combination therapy increasingly favored due to improved progression-free survival (PFS).
Regulatory Status
-
Approved by the FDA in 2011 for unresectable or metastatic melanoma with BRAF V600E mutation.
-
No current significant patent exclusivity extensions that delay generic entry; biosimilar competition is unlikely within the next 5 years.
Prescribing Trends
-
Use is driven by molecular testing to identify BRAF mutations, with over 70% of melanoma cases tested for BRAF status.
-
Adoption of combination therapy is growing, influencing Vemurafenib's standalone sales.
What Are the Price Trends and Projections for NDC 00169-4060?
Existing Price Points
-
The average wholesale price (AWP) for Vemurafenib in the U.S. ranged between $13,000 and $15,000 per patient per month in 2022.[3]
-
The list price for an annual course approximates $150,000, with actual costs varying depending on insurance coverage and negotiated discounts.
Price Drivers
-
Patent expiration or biosimilar entry could significantly lower prices, but no biosimilar approval has been announced as of late 2022.
-
Reimbursement policies and formulary placement influence net prices; payers tend to favor combination therapies, which could reduce Vemurafenib's standalone utilization.
Future Price Projections
| Period |
Price Trend |
Notes |
| 2023-2025 |
Slight decline, 5-10% annually |
Increased competition, policy pressure on high-cost therapies |
| 2025-2030 |
Potential stabilization or further decline (10-20%), contingent on biosimilar approvals |
Biosimilar or generic alternatives could drive prices down significantly |
| 2030+ |
Likely reduced, $5,000-$8,000/month |
Patent and exclusivity protections expire, generic production feasible post-2030 |
Key Factors Influencing Future Prices
-
Patent and exclusivity status: The primary patent for Vemurafenib is expected to expire around 2025-2026, opening the door to generic competition.
-
Regulatory approvals: Any additional indications or label expansions could maintain or increase demand, counteracting price pressures.
-
Market dynamics: Uptake of combination therapies and molecular diagnostics will influence Vemurafenib’s share, impacting the demand-driven pricing landscape.
What Is the Outlook for Market Growth and Pricing?
-
The melanoma targeted therapy segment is expected to grow at a compound annual growth rate (CAGR) of around 6% from 2023 to 2030, driven by expanded indications and improved diagnostics.[4]
-
Price erosion is projected as biosimilars enter the market post-2025, with reductions of up to 50% possible within five years of biosimilar approval.
-
Environmental considerations, such as value-based pricing models and payer negotiations, will further suppress or stabilize prices.
What Are the Regulatory and Policy Influences on Price Projections?
Patent and Exclusivity
- Original patent for Vemurafenib is expected to expire between 2025-2026 in the U.S., allowing biosimilar competition.
Reimbursement Policies
- Medicare and private insurers increasingly favor integrated treatment pathways, favoring combination therapies over monotherapy, which could decrease standalone Vemurafenib utilization and affect pricing.
Cost-Effectiveness and Value-Based Pricing
-
Payers are applying more rigorous cost-effectiveness assessments, with some considering prices exceeding $150,000 per quality-adjusted life year (QALY) as high.
-
New value-based contracts may limit pricing growth or accelerate discounts.
Key Takeaways
-
Vemurafenib (NDC 00169-4060) remains a high-revenue agent for melanoma with a strong market presence until patent expiration.
-
Current list prices average $13,000–$15,000/month, with future prices likely to decline significantly after patent expiry, potentially reaching $5,000–$8,000/month by 2030.
-
Competitive pressures from biosimilars, regulatory changes, and shifting prescribing practices will influence market share and pricing.
-
Growth in the segment is driven by increased molecular testing, expanding indications, and combination therapies, whereas price reductions are driven by patent expirations.
FAQs
1. When will biosimilar versions of Vemurafenib become available?
Biosmilar development is in regulatory stages, with approval expected around 2025-2026, following patent expiry.
2. How does combination therapy impact Vemurafenib sales?
The trend toward combined BRAF and MEK inhibition reduces standalone Vemurafenib prescriptions but can extend overall melanoma treatment sales.
3. Are there any upcoming regulatory changes that could affect pricing?
Regulatory focus on cost-effectiveness and value-based pricing may influence reimbursement policies and pricing negotiations.
4. What factors could delay patent expiration?
Secondary patents or extensions may delay generic entry; however, legal challenges in patent originality could shorten exclusivity periods.
5. How do current price levels compare internationally?
Prices tend to be higher in the U.S., averaging $13,000–$15,000/month, versus lower in Europe and other markets due to different reimbursement systems and pricing regulations.
References
[1] Market Research Future. "Melanoma Treatment Market size." 2022.
[2] IQVIA. "U.S. Pharmaceutical Sales Data," 2022.
[3] GoodRx. "Vemurafenib prices," 2022.
[4] Grand View Research. "Oncology Drugs Market Trends," 2022.
